Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the best stocks added in a Growth Stock Portfolio. BMO Capital ...

In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $339.39, a high estimate of $500.00, and a low estimate of $268.00.

Shares of Incyte Corp. rallied 4.83% to $70.81 Thursday, on what proved to be an all-around positive trading session for the ...

See the latest Alnylam Pharmaceuticals Inc stock price (ALNY:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics.

Alnylam Pharmaceuticals (NasdaqGS:ALNY) recently announced the appointment of Dr. Pushkal Garg as Executive Vice President and Chief Research and Development Officer to accelerate its R&D efforts.

Amvuttra is the first and only RNA interference (RNAi) therapeutic approved by the EC for both the cardiomyopathy and the polyneuropathy manifestations of ATTR amyloidosis and hereditary transthyretin ...

Alnylam Pharmaceuticals named Pushkal Garg executive vice president and chief research and development officer. The company said Wednesday that Garg will help oversee an integrated R&D organization to ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to ...

Alnylam Pharmaceuticals Inc. Annual cash flow by MarketWatch. View ALNY net cash flow, operating cash flow, operating expenses and cash dividends.

Alnylam Pharmaceuticals Inc has a consensus price target of $317.04 based on the ratings of 27 analysts. The high is $500 issued by HC Wainwright & Co. on April 2, 2025.

Thirty-three life sciences companies are slated to receive $29.9 million in tax incentives for creating 1,519 new industry ...